L3VLUP
ProSign in

MXCT · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MXCTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MXCT
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterMXCTVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 20213 holders, $110m35 holders, $10.1bn
Q4 20213 holders, $96m28 holders, $12.4bn
Q1 20223 holders, $54m23 holders, $16.1bn
Q2 20222 holders, $20m25 holders, $18.1bn
Q3 20223 holders, $29m22 holders, $18.4bn
Q4 20223 holders, $23m28 holders, $18.4bn
Q1 20234 holders, $18m26 holders, $21.4bn
Q2 20232 holders, $15m27 holders, $24.7bn
Q3 20231 holders, $6.6m33 holders, $24.3bn
Q4 2023none listed holders, n.a.32 holders, $28.6bn
Q1 2024none listed holders, n.a.31 holders, $29.8bn
Q2 2024none listed holders, n.a.29 holders, $33.4bn
Q3 2024none listed holders, n.a.27 holders, $33.5bn
Q4 2024none listed holders, n.a.26 holders, $28.5bn
Q1 2025none listed holders, n.a.21 holders, $35.4bn
Q2 2025none listed holders, n.a.21 holders, $32.3bn
Q3 2025none listed holders, n.a.22 holders, $25.9bn
Q4 2025none listed holders, n.a.26 holders, $31.8bn
Q1 2026none listed holders, n.a.25 holders, $31.8bn
Q2 2026none listed holders, n.a.26 holders, $34.6bn
MXCT

Maxcyte Inc

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
29
Reported value
$33.4bn
Buyers
12
Sellers
18

Breadth -6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 29 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only MXCT (0)

None.

Only VRTX (29)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →